AOD-9604 is a synthetic fragment of the C-terminus of human growth hormone that has been studied as a way to isolate the hormone's fat-mobilizing activity from its broader endocrine actions. This article reviews how experimental models describe that lipolytic activity and why researchers report it occurring without measurable changes in the IGF-1 signaling axis.

Why isolate growth hormone's lipolytic domain?

Interest in fat metabolism intensified as population studies charted a steep, sustained rise in adiposity: a pooled analysis of 200 countries reported that age-standardized obesity prevalence rose from roughly 3.2% in men and 6.4% in women in 1975 to about 10.8% and 14.9% respectively by 2014.¹ Against that backdrop, the metabolic actions of growth hormone (GH) drew attention because GH has a long-recognized ability to shift the body toward lipid mobilization.

Full-length human growth hormone, however, is metabolically complex. In human physiology it acts as a counter-regulatory hormone: alongside stimulating lipolysis, it antagonizes the effects of insulin on glucose handling and drives the production of insulin-like growth factor 1 (IGF-1), which mediates much of GH's growth-promoting and mitogenic activity.⁴ This coupling of fat mobilization to insulin resistance and IGF-1 output is precisely what makes intact GH a blunt instrument for studying lipolysis in isolation.

The research strategy behind AOD-9604 was to dissect the molecule: to take only the portion of the GH sequence associated with lipid regulation and ask whether that fragment could reproduce the lipolytic signal while leaving the rest of the endocrine cascade untouched.² The compound therefore functions less as a finished intervention and more as a mechanistic probe for separating one arm of GH biology from the others.

How AOD-9604 mirrors the C-terminal fragment

AOD-9604 was designed as a synthetic analogue of the lipolytic domain located at the C-terminus of human growth hormone.² Structurally it reproduces the short sequence at the tail end of the GH molecule (broadly, residues 177-191) that earlier structure-activity work associated with fat metabolism, with a modification intended to stabilize the peptide. Critically, it does not contain the discontinuous binding surfaces spread across the full-length hormone that are required to engage and cross-link the growth hormone receptor.

This design choice has a direct mechanistic consequence. Growth hormone signals by binding one receptor molecule and then recruiting a second, bringing the two receptor chains together — a step called receptor dimerization — which activates the intracellular JAK2 kinase and downstream STAT5 transcription factors.⁴ A short C-terminal fragment lacks the surfaces needed to drive that pairing, so the classical GH-receptor signaling cascade is not expected to fire. The fragment can therefore be studied as a domain-level tool rather than a receptor agonist.

Early metabolic characterization supported this separation. In obese Zucker rats, daily oral administration of the analogue over 19 days was associated with a marked reduction in body-weight gain relative to controls, and adipose tissue from treated animals showed increased lipolytic activity.² In the same work, and in contrast to chronic treatment with intact human GH, the fragment was reported not to impair insulin sensitivity as measured by euglycemic clamp — an early signal that the lipolytic and the glucose-disrupting arms of GH biology could be uncoupled in a research model.²

β3-adrenergic and adipocyte pathways

The most detailed mechanistic account of how the fragment engages fat cells comes from work in obese mice and in mice genetically lacking the β3-adrenergic receptor (β3-AR), the principal lipolytic receptor on rodent adipocytes.³ That study reported three observations that together shaped the current mechanistic picture.

β3-adrenergic receptor expression

Both human GH and AOD-9604 were associated with increased β3-AR messenger RNA in adipose tissue following chronic administration. In obese animals, the normally repressed levels of β3-AR expression were reported to rise toward the levels seen in lean controls.³ The interpretation offered is that the fragment does not act as a direct β3 agonist but instead restores the expression of a receptor system that governs how responsive fat cells are to endogenous lipolytic signals such as catecholamines.

Downstream lipolytic sensitivity

Greater β3-AR availability is proposed to amplify the intracellular cascade that hydrolyzes stored triglyceride and releases free fatty acids. In this framing, the fragment tunes the sensitivity of the adipocyte rather than forcing a signal through the receptor itself — a distinction that matters for interpreting how, and under what conditions, lipolysis is observed.³

A parallel, receptor-independent component

The clearest evidence that β3-AR is not the whole story came from the knockout animals. Chronic treatment with GH or AOD-9604 failed to reproduce the body-weight and lipolysis changes in β3-AR knockout mice that were seen in wild-type controls — yet in an acute experiment, AOD-9604 still increased energy expenditure and fat oxidation in those same knockout animals.³ The authors concluded that the lipolytic actions are not mediated directly through β3-AR, even though the fragment raises β3-AR expression, pointing to at least one additional intracellular route influencing substrate oxidation.³

Why the effect is described as IGF-1 independent

The claim that AOD-9604 mobilizes lipid without engaging the IGF-1 axis is grounded in the molecule's design as much as in its measured outputs. Because the fragment lacks the surfaces needed for growth hormone receptor dimerization, the JAK2/STAT5 pathway that normally couples GH signaling to hepatic IGF-1 production is not expected to be initiated.⁴ IGF-1 is the principal downstream effector of GH's growth-promoting activity, so a molecule that does not trigger that cascade would not be predicted to raise circulating IGF-1.

This is the mechanistic feature that most distinguishes AOD-9604 from the secretagogue peptides that occupy an adjacent research space. Growth-hormone-releasing analogues such as tesamorelin act upstream to stimulate the release of endogenous GH and, through it, IGF-1; the AOD-9604 fragment is studied precisely because it is designed to avoid that upstream, IGF-1-raising route. Comparing the two classes is a common way for laboratories to frame what "IGF-1 independent" means in practice.

Converging lines of reasoning support the separation. The fragment is not expected to displace labeled GH in receptor-competition assays or to provoke proliferative responses in GH-responsive cell lines, both of which are hallmarks of engaging the receptor. And in the rodent metabolic studies, the lipolytic and weight outcomes appeared without the insulin-desensitizing signature that accompanies intact GH exposure² — a pattern consistent with lipid modulation running independently of the systemic GH/IGF-1 program.⁴

Glucose tolerance and metabolic-neutrality data

A second strand of evidence for mechanistic selectivity comes from carbohydrate metabolism. Intact growth hormone is reliably diabetogenic: by antagonizing insulin's action on glucose uptake and driving free fatty acid flux, it induces a measurable degree of insulin resistance, which is part of GH's normal role in defending against hypoglycemia during fasting and stress.⁴ A fragment that reproduced GH's lipolytic action but not this glucose-disrupting effect would be strong evidence that the two are separable.

That is broadly what the preclinical record describes. In the Zucker rat clamp studies, chronic AOD-9604 did not impair insulin sensitivity in the way intact GH did.² During its clinical development the compound advanced into phase II obesity trials, where it was positioned as a growth-hormone fragment being tested for effects on adipose tissue function and fatty acid metabolism.⁶⁷ Contemporary reviews of anti-obesity compounds under development listed AOD-9604 among agents of interest specifically because of this proposed metabolic profile.⁸

Contested findings and model limits

Honest appraisal requires noting where the picture is unsettled. The mechanistic model above is drawn largely from a small number of rodent studies conducted by overlapping research groups in the early 2000s, and much of what circulates about the fragment traces back to these same sources. Independent replication of the specific human-relevant lipolytic claims is thin, and the clinical program did not produce a marketed product.⁷

The underlying assumption that GH mobilizes fat by acting directly on adipocytes has itself been questioned by more recent work. In a 2023 study, growth hormone stimulated lipolysis in intact mice but had no measurable effect on basal or isoproterenol-induced lipolysis when applied to cultured adipose tissue explants or isolated adipocytes, and did not enhance β-adrenergic-mediated lipolysis in that setting.⁵ The authors argued this weighs against the idea that GH stimulates lipolysis by acting directly on the fat cell or by amplifying β-adrenergic signaling there.⁵ If the parent hormone's adipocyte-direct mechanism is contested, then mechanistic accounts of its fragment inherit that uncertainty and should be read cautiously.

None of this negates the core, well-documented observations — that the fragment corresponds to a defined C-terminal domain, that it does not engage the GH receptor's dimerization step, and that it did not reproduce GH's insulin-desensitizing effect in the rodent clamp work. But it does mean the "how" of the lipolytic signal remains an open research question rather than a settled fact, which is the appropriate frame for any laboratory designing new experiments.

How laboratories evaluate the question

Researchers examining whether a compound acts independently of the IGF-1 axis typically combine several complementary readouts. Biomarker panels track circulating IGF-1 across doses and durations to test whether the endocrine arm is engaged. Receptor-binding and competition assays probe whether the molecule occupies the growth hormone receptor. Cell-proliferation assays in GH-responsive lines test for mitogenic signaling. And metabolic assays — oral glucose tolerance tests, fasting glucose and insulin, and clamp techniques — assess whether glucose handling is disturbed in the way intact GH disturbs it.²⁴

For the lipolytic side of the question, knockout models remain the sharpest tool. The β3-AR knockout comparison is instructive precisely because it dissociates two things that are otherwise confounded: it showed that chronic weight and lipolysis effects depended on β3-AR, while an acute energy-expenditure effect did not.³ Reproducibility across these readouts — and consistent, well-characterized starting material — is what allows a laboratory to distinguish a genuine domain-level effect from an artifact of a single assay. Consistent input material is one reason careful sourcing matters for this kind of mechanistic work; researchers evaluating the fragment often standardize on a single characterized AOD-9604 reference lot for that reason.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.